Wei Lin

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Martin Reck, Tony Mok, Makoto Nishio et al. · The Lancet Respiratory Medicine · 2019 · 939 citations

Medicine, Oncology, Pharmacology +17

Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy

Qian Gong, Qinglin Ou, Shiming Ye et al. · The Journal of Immunology · 2005 · 540 citations · Full text

Life Sciences, Cell Biology, Immunology +16

B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

Scott E. Strome, Haidong Dong, Hideto Tamura et al. · PubMed · 2003 · 492 citations

Life Sciences, Immunology, Oncology +11

Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics

Glynn Dennis, Cécile Holweg, Sarah Kummerfeld et al. · Arthritis Research & Therapy · 2014 · 373 citations · Full text

Medicine, Immunology, Internal Medicine +17

OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC

Vassiliki A. Papadimitrakopoulou, Manuel Cobo, Rodolfo Bordoni et al. · Journal of Thoracic Oncology · 2018 · 120 citations · Full text

Medicine, Oncology, Pharmacology +10